|
H2AC11 expression profile based on
|
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. Published 2016 May 10. doi:10.1038/ncomms11479
| Comparison | Statistical significance |
| ER negative-vs-ER positive | 3.021346E-02 |
|
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. Published 2016 May 10. doi:10.1038/ncomms11479
| Comparison | Statistical significance |
| HER2 Negative-vs-HER2 Positive | 2.003572E-02 |
|
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. Published 2016 May 10. doi:10.1038/ncomms11479
| Comparison | Statistical significance |
| Non-TNBC tumors-vs-TNBC tumors | 1.593220E-01 |
|
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. Published 2016 May 10. doi:10.1038/ncomms11479
| Comparison | Statistical significance |
| PR-Negative-vs-ER-Positive | 6.598211E-03 |
|
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. Published 2016 May 10. doi:10.1038/ncomms11479
| Comparison | Statistical significance |
| Pre Menopause-vs-Post Menopause | 6.379486E-04 |
|
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. Published 2016 May 10. doi:10.1038/ncomms11479
| Comparison | Statistical significance |
| No Recurrence-vs-Recurred | 8.209752E-01 |
|
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. Published 2016 May 10. doi:10.1038/ncomms11479
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Grade 1-vs-Grade 2 |
1.574101E-01 |
| Grade 1-vs-Grade 3 |
1.13202588738433E-06 |
| Grade 2-vs-Grade 3 |
1.35081383786568E-07 |
|
|
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. Published 2016 May 10. doi:10.1038/ncomms11479
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| 21-40yrs-vs-41-60yrs |
2.211020E-04 |
| 21-40yrs-vs-61-80yrs |
1.35494342768759E-05 |
| 21-40yrs-vs-81-100yrs |
7.21014629357934E-05 |
| 41-60yrs-vs-61-80yrs |
1.235293E-01 |
| 41-60yrs-vs-81-100yrs |
2.055088E-01 |
| 61-80yrs-vs-81-100yrs |
6.851340E-01 |
|
|
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. Published 2016 May 10. doi:10.1038/ncomms11479
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| ER-HER2- -vs- ER+ HER2- Low Prolif |
3.98777848943877E-05 |
| ER-HER2- -vs- ER+ HER2- High Prolif |
5.207430E-02 |
| ER-HER2- -vs- HER2+ |
4.721788E-01 |
| ER+ HER2- Low Prolif-vs- ER+ HER2- High Prolif |
7.1522508523075E-11 |
| ER+ HER2- Low Prolif-vs- HER2+ |
4.25679308084474E-05 |
| ER+ HER2- High Prolif -vs- HER2+ |
3.513062E-01 |
|
|
*
Please note that low number(<10) of samples considered.
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. Published 2016 May 10. doi:10.1038/ncomms11479
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Stage0-vs-Stage1 |
4.558564E-01 |
| Stage0-vs-Stage2 |
4.777762E-01 |
| Stage0-vs-Stage3 |
5.186650E-01 |
| Stage0-vs-Stage4 |
4.606367E-01 |
| Stage1-vs-Stage2 |
4.037033E-01 |
| Stage1-vs-Stage3 |
2.150679E-01 |
| Stage1-vs-Stage4 |
9.928666E-01 |
| Stage2-vs-Stage3 |
4.225188E-01 |
| Stage2-vs-Stage4 |
8.416129E-01 |
| Stage3-vs-Stage4 |
6.004845E-01 |
|
|
*
Please note that low number(<10) of normal samples considered.
Pereira B, Chin SF, Rueda OM, et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun. 2016;7:11479. Published 2016 May 10. doi:10.1038/ncomms11479
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal like-vs-LumA |
7.132726E-01 |
| Normal like-vs-LumB |
4.56982407108676E-05 |
| Normal like-vs-HER2 enriched |
9.118829E-03 |
| Normal like-vs-Basal like |
5.837544E-02 |
| Normal like-vs-Non Claudin |
5.755586E-01 |
| Normal like-vs-Claudin_Low |
7.704463E-01 |
| LumA-vs-LumB |
1.24443825928154E-10 |
| LumA-vs-HER2 enriched |
8.78040028302968E-05 |
| LumA-vs-Basal like |
1.413354E-03 |
| LumA-vs-Non Claudin |
5.209845E-01 |
| LumA-vs-Claudin_Low |
3.219264E-01 |
| LumB-vs-HER2 enriched |
1.694346E-01 |
| LumB-vs-Basal like |
1.121750E-02 |
| LumB-vs-Non Claudin |
6.451052E-01 |
| LumB-vs-Claudin_Low |
1.57979294161646E-06 |
| HER2 enriched-vs-Basal |
3.432172E-01 |
| HER2 enriched-vs-Non Claudin |
8.918273E-01 |
| HER2 enriched-vs-Claudin_Low |
4.422938E-03 |
| Basal like-vs-Non Claudin |
9.268455E-01 |
| Basal like-vs-Claudin_Low |
4.242435E-02 |
| Non Claudin-vs-Claudin_Low |
6.180017E-01 |
|
|
